Journal
JOURNAL OF BIOCHEMISTRY
Volume 150, Issue 4, Pages 371-374Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jb/mvr086
Keywords
APOBEC3C (A3C); hepatitis B virus (HBV) core protein; recombinant HBV vector; capsid targeted viral inactivation (CTVI)
Categories
Funding
- National Natural Science Foundation of China [30872255, 30571667]
Ask authors/readers for more resources
We tested the capsid targeted viral inactivation method as an anti-HBV strategy. HepG2 cells were cotransfected with HBV expression plasmid and the plasmid encoding fusion protein of either Core-A3C or Core-humanized renilla GFP (hrGFP). Core-A3C had substantial effect on HBV DNA levels. In the HepG2 cells expressing Core-A3C, the number of G-to-A mutations increased dramatically, whereas other nucleotide substitutions were rare. In addition, Core-A3C substantially inhibited HBV production intracellularly and in culture supernatant. These results suggest that Core-A3C may be a candidate as a novel antiviral agent against human HBV infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available